Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Beyond tissue biopsy: a diagnostic framework to address tumor heterogeneity in lung cancer.

Voigt W, Manegold C, Pilz L, Wu YL, Müllauer L, Pirker R, Filipits M, Niklinski J, Petruzelka L, Prosch H.

Curr Opin Oncol. 2020 Jan;32(1):68-77. doi: 10.1097/CCO.0000000000000598.

PMID:
31714259
2.

From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer.

Pirker R, Filipits M.

ESMO Open. 2019 Sep 8;4(5):e000548. doi: 10.1136/esmoopen-2019-000548. eCollection 2019. No abstract available.

3.

Stromal coexpression of uPA/PAI-1 protein predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer.

Singer CF, Filipits M, Jahn SW, Abete L, Jakesz R, Greil R, Bauernhofer T, Kwasny W, Seifert M, Fitzal F, Kastner M, Schmitt M, Moinfar F, Gnant M.

Breast. 2019 Aug;46:101-107. doi: 10.1016/j.breast.2019.05.007. Epub 2019 May 3.

PMID:
31132475
4.

Prediction of Distant Recurrence Using EndoPredict Among Women with ER+, HER2- Node-Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only.

Filipits M, Dubsky P, Rudas M, Greil R, Balic M, Bago-Horvath Z, Singer CF, Hlauschek D, Brown K, Bernhisel R, Kronenwett R, Lancaster JM, Fitzal F, Gnant M.

Clin Cancer Res. 2019 Jul 1;25(13):3865-3872. doi: 10.1158/1078-0432.CCR-19-0376. Epub 2019 May 7.

PMID:
31064782
5.

Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.

Sestak I, Martín M, Dubsky P, Kronenwett R, Rojo F, Cuzick J, Filipits M, Ruiz A, Gradishar W, Soliman H, Schwartzberg L, Buus R, Hlauschek D, Rodríguez-Lescure A, Gnant M.

Breast Cancer Res Treat. 2019 Jul;176(2):377-386. doi: 10.1007/s10549-019-05226-8. Epub 2019 Apr 30.

6.

EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR.

Buder A, Setinek U, Hochmair MJ, Schwab S, Kirchbacher K, Keck A, Burghuber OC, Pirker R, Filipits M.

Target Oncol. 2019 Apr;14(2):197-203. doi: 10.1007/s11523-019-00623-x.

7.

PIK3CA Mutational Status Is Associated with High Glycolytic Activity in ER+/HER2- Early Invasive Breast Cancer: a Molecular Imaging Study Using [18F]FDG PET/CT.

Magometschnigg H, Pinker K, Helbich T, Brandstetter A, Rudas M, Nakuz T, Baltzer P, Wadsak W, Hacker M, Weber M, Dubsky P, Filipits M.

Mol Imaging Biol. 2019 Oct;21(5):991-1002. doi: 10.1007/s11307-018-01308-z.

PMID:
30652258
8.

Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.

Hochmair MJ, Buder A, Schwab S, Burghuber OC, Prosch H, Hilbe W, Cseh A, Fritz R, Filipits M.

Target Oncol. 2019 Feb;14(1):75-83. doi: 10.1007/s11523-018-0612-z.

9.

ERRα promotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors.

Vargas G, Bouchet M, Bouazza L, Reboul P, Boyault C, Gervais M, Kan C, Benetollo C, Brevet M, Croset M, Mazel M, Cayrefourcq L, Geraci S, Vacher S, Pantano F, Filipits M, Driouch K, Bieche I, Gnant M, Jacot W, Aubin JE, Duterque-Coquillaud M, Alix-Panabières C, Clézardin P, Bonnelye E.

Oncogene. 2019 Feb;38(7):950-964. doi: 10.1038/s41388-018-0579-3. Epub 2018 Nov 26.

10.

LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer.

Seymour L, Le Teuff G, Brambilla E, Shepherd FA, Soria JC, Kratzke R, Graziano S, Douillard JY, Rosell R, Reiman A, Lacas B, Lueza B, Aviel-Ronen S, McLeer A, Le Chevalier T, Pirker R, Filipits M, Dunant A, Pignon JP, Tsao MS; LACE-Bio Steering Committee.

Clin Lung Cancer. 2019 Mar;20(2):66-73.e6. doi: 10.1016/j.cllc.2018.10.001. Epub 2018 Oct 11.

PMID:
30414783
11.

Adjuvant Therapy in Patients With Completely Resected Non-small-cell Lung Cancer: Current Status and Perspectives.

Pirker R, Filipits M.

Clin Lung Cancer. 2019 Jan;20(1):1-6. doi: 10.1016/j.cllc.2018.09.016. Epub 2018 Sep 24.

PMID:
30309777
12.

PD-1 and PD-L1 Protein Expression Predict Survival in Completely Resected Lung Adenocarcinoma.

Zaric B, Brcic L, Buder A, Brandstetter A, Buresch JO, Traint S, Kovacevic T, Stojsic V, Perin B, Pirker R, Filipits M.

Clin Lung Cancer. 2018 Nov;19(6):e957-e963. doi: 10.1016/j.cllc.2018.08.014. Epub 2018 Aug 22.

PMID:
30197262
13.

Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study.

Filipits M, Dafni U, Gnant M, Polydoropoulou V, Hills M, Kiermaier A, de Azambuja E, Larsimont D, Rojo F, Viale G, Toi M, Harbeck N, Prichard KI, Gelber RD, Dinh P, Zardavas D, Leyland-Jones B, Piccart-Gebhart MJ, Dowsett M; TransHERA investigators.

Clin Cancer Res. 2018 Jul 1;24(13):3079-3086. doi: 10.1158/1078-0432.CCR-17-3473. Epub 2018 Mar 12.

14.

Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC.

Buder A, Hochmair MJ, Schwab S, Bundalo T, Schenk P, Errhalt P, Mikes RE, Absenger G, Patocka K, Baumgartner B, Setinek U, Burghuber OC, Prosch H, Pirker R, Filipits M.

J Thorac Oncol. 2018 Jun;13(6):821-830. doi: 10.1016/j.jtho.2018.02.014. Epub 2018 Mar 2.

15.

Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.

Shepherd FA, Lacas B, Le Teuff G, Hainaut P, Jänne PA, Pignon JP, Le Chevalier T, Seymour L, Douillard JY, Graziano S, Brambilla E, Pirker R, Filipits M, Kratzke R, Soria JC, Tsao MS; LACE-Bio Collaborative Group.

J Clin Oncol. 2017 Jun 20;35(18):2018-2027. doi: 10.1200/JCO.2016.71.2893. Epub 2017 Apr 28.

16.

Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain.

Gojo J, Lötsch D, Spiegl-Kreinecker S, Pajtler KW, Neumayer K, Korbel P, Araki A, Brandstetter A, Mohr T, Hovestadt V, Chavez L, Kirchhofer D, Ricken G, Stefanits H, Korshunov A, Pfister SM, Dieckmann K, Azizi AA, Czech T, Filipits M, Kool M, Peyrl A, Slavc I, Berger W, Haberler C.

Neuro Oncol. 2017 Sep 1;19(9):1183-1194. doi: 10.1093/neuonc/nox027.

17.

Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer.

Singer CF, Tan YY, Fitzal F, Steger GG, Egle D, Reiner A, Rudas M, Moinfar F, Gruber C, Petru E, Bartsch R, Tendl KA, Fuchs D, Seifert M, Exner R, Balic M, Bago-Horvath Z, Filipits M, Gnant M; Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res. 2017 Jul 15;23(14):3676-3683. doi: 10.1158/1078-0432.CCR-16-2373. Epub 2017 Jan 31.

18.

PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.

Tsao MS, Le Teuff G, Shepherd FA, Landais C, Hainaut P, Filipits M, Pirker R, Le Chevalier T, Graziano S, Kratze R, Soria JC, Pignon JP, Seymour L, Brambilla E.

Ann Oncol. 2017 Apr 1;28(4):882-889. doi: 10.1093/annonc/mdx003.

19.

Electronic State of Sodium trans-[Tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) in Tumor, Liver and Kidney Tissue of a SW480-bearing Mouse.

Blazevic A, Hummer AA, Heffeter P, Berger W, Filipits M, Cibin G, Keppler BK, Rompel A.

Sci Rep. 2017 Jan 23;7:40966. doi: 10.1038/srep40966.

20.

Gamma Knife Radiosurgery in Recurrent Glioblastoma.

Frischer JM, Marosi C, Woehrer A, Hainfellner JA, Dieckmann KU, Eiter H, Wang WT, Mallouhi A, Ertl A, Knosp E, Filipits M, Kitz K, Gatterbauer B.

Stereotact Funct Neurosurg. 2016;94(4):265-272. Epub 2016 Oct 8.

PMID:
27721311
21.

Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice.

Pirker R, Filipits M.

Cancer Metastasis Rev. 2016 Mar;35(1):141-50. doi: 10.1007/s10555-016-9612-6. Review.

22.

Prognostic and Predictive Effect of TP53 Mutations in Patients with Non-Small Cell Lung Cancer from Adjuvant Cisplatin-Based Therapy Randomized Trials: A LACE-Bio Pooled Analysis.

Ma X, Le Teuff G, Lacas B, Tsao MS, Graziano S, Pignon JP, Douillard JY, Le Chevalier T, Seymour L, Filipits M, Pirker R, Jänne PA, Shepherd FA, Brambilla E, Soria JC, Hainaut P; LACE-Bio Collaborative Group.

J Thorac Oncol. 2016 Jun;11(6):850-61. doi: 10.1016/j.jtho.2016.02.002. Epub 2016 Feb 17.

23.

Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer.

Brambilla E, Le Teuff G, Marguet S, Lantuejoul S, Dunant A, Graziano S, Pirker R, Douillard JY, Le Chevalier T, Filipits M, Rosell R, Kratzke R, Popper H, Soria JC, Shepherd FA, Seymour L, Tsao MS.

J Clin Oncol. 2016 Apr 10;34(11):1223-30. doi: 10.1200/JCO.2015.63.0970. Epub 2016 Feb 1.

24.

Alectinib in RET-rearranged non-small cell lung cancer-Another progress in precision medicine?

Pirker R, Filipits M.

Transl Lung Cancer Res. 2015 Dec;4(6):797-800. doi: 10.3978/j.issn.2218-6751.2015.03.08.

25.

The potential of liquid biopsies.

Buder A, Tomuta C, Filipits M.

Curr Opin Oncol. 2016 Mar;28(2):130-4. doi: 10.1097/CCO.0000000000000267. Review.

PMID:
26730486
26.

Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors: A systematic review and meta-analysis.

Perisanidis C, Psyrri A, Cohen EE, Engelmann J, Heinze G, Perisanidis B, Stift A, Filipits M, Kornek G, Nkenke E.

Cancer Treat Rev. 2015 Dec;41(10):960-70. Review.

PMID:
26604093
27.

Expression of ARs in triple negative breast cancer tumors: a potential prognostic factor?

Giannos A, Filipits M, Zagouri F, Brandstetter A, Tsigginou A, Sotiropoulou M, Papaspyrou I, Sergentanis TN, Psaltopoulou T, Rodolakis A, Antsaklis A, Dimopoulos MA, Dimitrakakis C.

Onco Targets Ther. 2015 Jul 23;8:1843-7. doi: 10.2147/OTT.S78254. eCollection 2015.

28.

Myeloid STAT3 promotes formation of colitis-associated colorectal cancer in mice.

Pathria P, Gotthardt D, Prchal-Murphy M, Putz EM, Holcmann M, Schlederer M, Grabner B, Crncec I, Svinka J, Musteanu M, Hoffmann T, Filipits M, Berger W, Poli V, Kenner L, Bilban M, Casanova E, Müller M, Strobl B, Bayer E, Mohr T, Sexl V, Eferl R.

Oncoimmunology. 2015 Jan 22;4(4):e998529. eCollection 2015 Apr.

29.

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.

Gnant M, Sestak I, Filipits M, Dowsett M, Balic M, Lopez-Knowles E, Greil R, Dubsky P, Stoeger H, Rudas M, Jakesz R, Ferree S, Cowens JW, Nielsen T, Schaper C, Fesl C, Cuzick J.

Ann Oncol. 2015 Aug;26(8):1685-91. doi: 10.1093/annonc/mdv215. Epub 2015 May 1.

30.

EVI1 promotes tumor growth via transcriptional repression of MS4A3.

Heller G, Rommer A, Steinleitner K, Etzler J, Hackl H, Heffeter P, Tomasich E, Filipits M, Steinmetz B, Topakian T, Klingenbrunner S, Ziegler B, Spittler A, Zöchbauer-Müller S, Berger W, Wieser R.

J Hematol Oncol. 2015 Mar 21;8:28. doi: 10.1186/s13045-015-0124-6.

31.

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial.

Fitzal F, Filipits M, Rudas M, Greil R, Dietze O, Samonigg H, Lax S, Herz W, Dubsky P, Bartsch R, Kronenwett R, Gnant M.

Br J Cancer. 2015 Apr 14;112(8):1405-10. doi: 10.1038/bjc.2015.98. Epub 2015 Mar 24.

32.

PYK2 sustains endosomal-derived receptor signalling and enhances epithelial-to-mesenchymal transition.

Verma N, Keinan O, Selitrennik M, Karn T, Filipits M, Lev S.

Nat Commun. 2015 Feb 4;6:6064. doi: 10.1038/ncomms7064.

PMID:
25648557
33.

Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study.

Ghanim B, Klikovits T, Hoda MA, Lang G, Szirtes I, Setinek U, Rozsas A, Renyi-Vamos F, Laszlo V, Grusch M, Filipits M, Scheed A, Jakopovic M, Samarzija M, Brcic L, Stancic-Rokotov D, Kern I, Rozman A, Dekan G, Klepetko W, Berger W, Glasz T, Dome B, Hegedus B.

Br J Cancer. 2015 Mar 3;112(5):783-92. doi: 10.1038/bjc.2015.9. Epub 2015 Jan 29.

34.

Upregulation of osteoprotegerin expression correlates with bone invasion and predicts poor clinical outcome in oral cancer.

Russmueller G, Moser D, Würger T, Wrba F, Christopoulos P, Kostakis G, Seemann R, Stadler V, Wimmer G, Kornek G, Psyrri A, Filipits M, Perisanidis C.

Oral Oncol. 2015 Mar;51(3):247-53. doi: 10.1016/j.oraloncology.2014.11.010. Epub 2014 Dec 17.

PMID:
25532817
35.

Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients.

Blank PR, Filipits M, Dubsky P, Gutzwiller F, Lux MP, Brase JC, Weber KE, Rudas M, Greil R, Loibl S, Szucs TD, Kronenwett R, Schwenkglenks M, Gnant M.

Pharmacoeconomics. 2015 Feb;33(2):179-90. doi: 10.1007/s40273-014-0227-x.

36.

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma.

Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wöhrer A, Dieckmann K, Filipits M, Brandstetter A, Weller M, Kurscheid S, Hegi ME, Zielinski CC, Marosi C, Hainfellner JA, Preusser M, Wick W.

Neuro Oncol. 2015 Aug;17(8):1064-75. doi: 10.1093/neuonc/nou307. Epub 2014 Oct 29.

37.

Prediction of late distant recurrence after 5 years of endocrine treatment: a combined analysis of patients from the Austrian breast and colorectal cancer study group 8 and arimidex, tamoxifen alone or in combination randomized trials using the PAM50 risk of recurrence score.

Sestak I, Cuzick J, Dowsett M, Lopez-Knowles E, Filipits M, Dubsky P, Cowens JW, Ferree S, Schaper C, Fesl C, Gnant M.

J Clin Oncol. 2015 Mar 10;33(8):916-22. doi: 10.1200/JCO.2014.55.6894. Epub 2014 Oct 20.

PMID:
25332252
38.

Fatty acid synthase is a metabolic marker of cell proliferation rather than malignancy in ovarian cancer and its precursor cells.

Veigel D, Wagner R, Stübiger G, Wuczkowski M, Filipits M, Horvat R, Benhamú B, López-Rodríguez ML, Leisser A, Valent P, Grusch M, Hegardt FG, García J, Serra D, Auersperg N, Colomer R, Grunt TW.

Int J Cancer. 2015 May 1;136(9):2078-90. doi: 10.1002/ijc.29261. Epub 2014 Nov 3.

39.

Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy.

Schelch K, Hoda MA, Klikovits T, Münzker J, Ghanim B, Wagner C, Garay T, Laszlo V, Setinek U, Dome B, Filipits M, Pirker C, Heffeter P, Selzer E, Tovari J, Torok S, Kenessey I, Holzmann K, Grasl-Kraupp B, Marian B, Klepetko W, Berger W, Hegedus B, Grusch M.

Am J Respir Crit Care Med. 2014 Oct 1;190(7):763-72. doi: 10.1164/rccm.201404-0658OC.

PMID:
25188816
40.

Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing.

Patton S, Normanno N, Blackhall F, Murray S, Kerr KM, Dietel M, Filipits M, Benlloch S, Popat S, Stahel R, Thunnissen E.

Br J Cancer. 2014 Jul 15;111(2):413-20. doi: 10.1038/bjc.2014.353. Epub 2014 Jul 1.

41.

Late recurrences in early breast cancer: for whom and how long is endocrine therapy beneficial?

Knauer M, Filipits M, Dubsky P.

Breast Care (Basel). 2014 May;9(2):97-100. doi: 10.1159/000362482. Review.

42.

Low protein expression of MET in ER-positive and HER2-positive breast cancer.

Zagouri F, Brandstetter A, Moussiolis D, Chrysikos D, Dimitrakakis C, Tsigginou A, Marinopoulos S, Zografos GC, Sergentanis TN, Dimopoulos MA, Filipits M.

Anticancer Res. 2014 Mar;34(3):1227-31.

PMID:
24596364
43.

The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.

Filipits M, Nielsen TO, Rudas M, Greil R, Stöger H, Jakesz R, Bago-Horvath Z, Dietze O, Regitnig P, Gruber-Rossipal C, Müller-Holzner E, Singer CF, Mlineritsch B, Dubsky P, Bauernhofer T, Hubalek M, Knauer M, Trapl H, Fesl C, Schaper C, Ferree S, Liu S, Cowens JW, Gnant M; Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res. 2014 Mar 1;20(5):1298-305. doi: 10.1158/1078-0432.CCR-13-1845. Epub 2014 Feb 11.

44.

Significance of TP53 mutations as predictive markers of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer.

Ma X, Rousseau V, Sun H, Lantuejoul S, Filipits M, Pirker R, Popper H, Mendiboure J, Vataire AL, Le Chevalier T, Soria JC, Brambilla E, Dunant A, Hainaut P; IALT-Bio working group.

Mol Oncol. 2014 May;8(3):555-64. doi: 10.1016/j.molonc.2013.12.015. Epub 2014 Jan 15.

45.

New developments in the treatment of squamous cell lung cancer.

Filipits M.

Curr Opin Oncol. 2014 Mar;26(2):152-8. doi: 10.1097/CCO.0000000000000049. Review.

PMID:
24441504
46.

Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma.

Ghanim B, Hoda MA, Klikovits T, Winter MP, Alimohammadi A, Grusch M, Dome B, Arns M, Schenk P, Jakopovic M, Samarzija M, Brcic L, Filipits M, Laszlo V, Klepetko W, Berger W, Hegedus B.

Br J Cancer. 2014 Feb 18;110(4):984-90. doi: 10.1038/bjc.2013.815. Epub 2014 Jan 16.

47.

Clinical Neuropathology practice news 1-2014: pyrosequencing meets clinical and analytical performance criteria for routine testing of MGMT promoter methylation status in glioblastoma.

Preusser M, Berghoff AS, Manzl C, Filipits M, Weinhäusel A, Pulverer W, Dieckmann K, Widhalm G, Wöhrer A, Knosp E, Marosi C, Hainfellner JA.

Clin Neuropathol. 2014 Jan-Feb;33(1):6-14.

48.

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.

Gnant M, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W, Knauer M, Singer C, Jakesz R, Dubsky P, Fitzal F, Bartsch R, Steger G, Balic M, Ressler S, Cowens JW, Storhoff J, Ferree S, Schaper C, Liu S, Fesl C, Nielsen TO; Austrian Breast and Colorectal Cancer Study Group.

Ann Oncol. 2014 Feb;25(2):339-45. doi: 10.1093/annonc/mdt494. Epub 2013 Dec 16.

49.

Differential survival trends of stage II colorectal cancer patients relate to promoter methylation status of PCDH10, SPARC, and UCHL1.

Heitzer E, Artl M, Filipits M, Resel M, Graf R, Weißenbacher B, Lax S, Gnant M, Wrba F, Greil R, Dietze O, Hofbauer F, Böhm G, Höfler G, Samonigg H, Schaberl-Moser R, Balic M, Dandachi N.

Mod Pathol. 2014 Jun;27(6):906-15. doi: 10.1038/modpathol.2013.204. Epub 2013 Dec 6.

50.

The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.

Dubsky P, Brase JC, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Fisch K, Kronenwett R, Gnant M, Filipits M; Austrian Breast and Colorectal Cancer Study Group (ABCSG).

Br J Cancer. 2013 Dec 10;109(12):2959-64. doi: 10.1038/bjc.2013.671. Epub 2013 Oct 24.

Supplemental Content

Loading ...
Support Center